Chinnici A, Beneforti L, Pegoraro F, Trambusti I, Tondo A, Favre C, Coniglio ML, Sieni E. Approaching hemophagocytic lymphohistiocytosis. Front Immunol. 2023;14:1210041. https://doi.org/10.3389/fimmu.2023.1210041.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allen CE, Mcclain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology. 2015(1):177–182.

Jordan MB, Allen CE, Weitzman S, Filipovich AH, Mcclain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

El-Mallawany NK, Curry CV, Allen CE. Haemophagocytic lymphohistiocytosis and epstein-barr virus: a complex relationship with diverse origins, expression and outcomes. British Journal of Haematology. 2021.

Bergsten E, Horne AC, Aricó, Maurizio, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in hlh treatment: long term results of the cooperative hlh-2004 study. Blood. 2017;06:788349.

Google Scholar 

Trottestam H, Horne A, Aricò M, Egeler RM, Henter JI. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the hlh-94 treatment protocol. Blood. 2011;118(17):4577–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarah N, Nancy, Berliner. Targeting the inflammatory cascade in haemophagocytic lymphohistiocytosis. Lancet Haematol. 2019;6(12):e602–3.

Article  Google Scholar 

Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160(6):984–e9901.

Article  CAS  PubMed  Google Scholar 

Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (hlh): cd8 + t cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735–43.

Article  CAS  PubMed  Google Scholar 

Humblet-Baron S, Franckaert D, Dooley J, Ailal F, Bousfiha A, Deswarte C, Oleaga-Quintas C, Casanova JL, Bustamante J, Liston A. IFN-γ and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2019;143(6):2215–e22267.

Article  CAS  PubMed  Google Scholar 

Buatois V, Chatel L, Cons L, Lory S, Richard F, Guilhot F, Johnson Z, Bracaglia C, De Benedetti F, de Min C, Kosco-Vilbois MH, Ferlin WG. Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis. Translational research: J Lab Clin Med. 2017;180:37–e522.

Article  CAS  Google Scholar 

Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti MC, Fagioli F, Ahlmann M, Diaz D, Henry JL, De Benedetti M, Grom F, Lapeyre A, Jacqmin G, Ballabio P, M., de Min C. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020;382(19):1811–22.

Article  PubMed  Google Scholar 

Chandrakasan S, Jordan MB, Baker A, Behrens EM, Bhatla D, Chien M, Eckstein OS, Henry MM, Hermiston ML, Hinson AP, Leiding JW, Oladapo A, Patel SA, Pednekar P, Ray AK, Dávila Saldaña B, Sarangi SN, Walkovich KJ, Yee JD, Zoref-Lorenz A, Allen CE. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024;8(9):2248–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keenan C, Nichols KE, Albeituni S. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis. Front Immunol. 2021;12:614704.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Gu J, Liang X, Mao X, Wang Z, Huang W. Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH. Semin Hematol. 2020;57(1):26–30.

Article  PubMed  Google Scholar 

Song Y, Zhou F, Du F, Wang Z, Bai L, Yao Y, Liu L, Ma X, Chen S, Wu D, He X. Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis. Blood cancer J. 2024;14(1):70.

Article  PubMed  PubMed Central  Google Scholar 

Wei A, Ma H, Li Z, Zhang L, Zhang Q, Wang D, Lian H, Zhang R, Wang T. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children. Int J Hematol. 2020;112(4):568–76.

Article  CAS  PubMed  Google Scholar 

Wang J, Wang Y, Wu L, Wang X, Jin Z, Gao Z, Wang Z. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105(5):e210–2.

Article  PubMed  Google Scholar